$2.57
▲ +$0.01
(+0.39%)
Vol 138K
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$165.9M
ROE
-129.3%
Margin
-98125.0%
D/E
0.00
Beta
0.04
52W
$2–$9
Wall Street Consensus
12 analysts · Apr 20262
Strong Buy
9
Buy
1
Hold
0
Sell
0
Strong Sell
91.7%
Buy Rating
Price Chart
Similar Stocks
AGEN
Agenus Inc
$106.8M
EQ
Equillium Inc
$94.4M
HUMA
Humacyte Inc
$185.4M
IMDX
Insight Molecular Diagnostics Inc
$215.0M
PEPG
PepGen Inc
$447.6M
SGMO
Sangamo Therapeutics Inc
$141.3M
BMEA
Biomea Fusion Inc
$87.7M
KPTI
Karyopharm Therapeutics Inc
$125.5M
CRDF
Cardiff Oncology Inc
$189.3M
CADL
Candel Therapeutics Inc
$310.2M
Earnings
Beat rate: 60.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.22 | $-0.25 | $-0.03 |
| Sep 2025 | $-0.22 | $-0.21 | +$0.01 |
| Jun 2025 | $-0.22 | $-0.20 | +$0.02 |
| Mar 2025 | $-0.25 | $-0.21 | +$0.04 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -107.6% | -107.6% | -107.6% | -107.6% | -107.6% | -129.3% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | -98125.0% | -98125.0% | -98125.0% | -98125.0% | -98125.0% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 4.18 | 4.18 | 4.18 | 4.18 | 4.18 | 4.20 |
Key Ratios
ROA (TTM)
-97.4%
P/S (TTM)
20738.22
P/B
3.1
EPS (TTM)
$-0.88
CF/Share
$-1.00
52W High
$8.54
52W Low
$1.99
$1.99
52-Week Range
$8.54
How does GNLX compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
GNLX valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
20738.2
▲
161287%
above
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
3.1
▲
26%
above
peers
(2.5)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
GNLX profitability vs Biotechnology peers
ROE
-129.3%
▼
92%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-98125.0%
▼
34120%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-97.4%
▼
108%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
GNLX financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
4.2
▼
5%
below
peers
(4.4)
vs Peers
vs Industry
In line
Beta
0.0
▼
96%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
GNLX fundamentals radar
GNLX
Peer median
Industry
GNLX profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
GNLX vs peers: key metrics
Latest News
No related news yet